--- title: "Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting | BCYC Stock News" type: "News" locale: "en" url: "https://longbridge.com/en/news/283520201.md" description: "Bicycle Therapeutics plc (NASDAQ: BCYC) announced its participation in the 2026 ASCO Annual Meeting, featuring an oral presentation and multiple poster presentations on its innovative therapeutics. Key presentations include interim analysis results from studies on zelenectide pevedotin (BT8009) in patients with advanced urothelial carcinoma. The meeting will take place from May 29 to June 2 in Chicago, with details available on the company's website." datetime: "2026-04-21T06:31:00.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/283520201.md) - [en](https://longbridge.com/en/news/283520201.md) - [zh-HK](https://longbridge.com/zh-HK/news/283520201.md) --- # Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting | BCYC Stock News CAMBRIDGE, England & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced an oral presentation and multiple poster presentations across five abstracts at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting, taking place May 29–June 2 in Chicago. **Presentation Details:** **Title**: Interim analysis results from Duravelo-2: Zelenectide pevedotin (zele; BT8009) + pembrolizumab in patients (pts) with previously untreated locally advanced/metastatic urothelial carcinoma (la/mUC) **Type**: Rapid Oral Abstract Session **Session:** Genitourinary Cancer – Kidney and Bladder **Date and Time**: Monday, June 1, 8:30-8:36 a.m. CT **Abstract Number**: 4516 **Lead Author**: Yohann Loriot, M.D., Institute Gustave Roussy **Title**: Interim analysis results from Duravelo-2: zelenectide pevedotin (zele; BT8009) in patients (pts) with previously treated locally advanced/metastatic urothelial carcinoma (la/mUC) **Type**: Poster Session **Session:** Genitourinary Cancer – Kidney and Bladder **Date and Time**: Sunday, May 31, 9 a.m.-12 p.m. CT **Abstract Number**: 4566 **Lead Author**: Dan Petrylak, M.D., Yale School of Medicine **Title**: Zelenectide pevedotin (BT8009) monotherapy in previously treated metastatic urothelial carcinoma (mUC): Update on Duravelo-1 **Type**: Poster Session **Session:** Genitourinary Cancer – Kidney and Bladder **Date and Time**: Sunday, May 31, 9 a.m.-12 p.m. CT **Abstract Number**: 4563 **Lead Author**: Oscar Reig Torras, M.D., Hospital Clínic de Barcelona **Title**: Zelenectide pevedotin (BT8009) plus pembrolizumab in 1L cisplatin-ineligible locally advanced/metastatic urothelial carcinoma: Update on Duravelo-1 B7 **Type**: Poster Session **Session:** Genitourinary Cancer – Kidney and Bladder **Date and Time**: Sunday, May 31, 9 a.m.-12 p.m. CT **Abstract Number**: 4564 **Lead Author**: Ignacio Duran, M.D., Hospital Universitario Marqués de Valdecilla **Title**: Identify optimized dosage for zelenectide pevedotin in locally advanced/metastatic urothelial carcinoma (la/mUC) using quantitative analyses **Type**: Poster Session **Session:** Genitourinary Cancer – Kidney and Bladder **Date and Time**: Sunday, May 31, 9 a.m.-12 p.m. CT **Abstract Number**: 4567 **Lead Author**: Yasong Lu, Ph.D., Bicycle Therapeutics The presentations will be made available in the Publications section of the Bicycle Therapeutics website on the morning of each session. **About Bicycle Therapeutics** Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a novel class of medicines, referred to as Bicycle® molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. This constraint facilitates target binding with high affinity and selectivity, making Bicycle molecules attractive candidates for drug development. The company is evaluating nuzefatide pevedotin, formerly BT5528, a Bicycle® Drug Conjugate (BDC®) targeting EphA2, a historically undruggable target; a pipeline of other bicycle-based conjugate molecules, including Bicycle® Radioconjugates (BRC®) for radiopharmaceutical use; zelenectide pevedotin (formerly BT8009), a BDC® targeting Nectin-4, a well-validated tumor antigen; BT7480, a Bicycle Tumor-Targeted Immune Cell Agonist® (Bicycle TICA®) targeting Nectin-4 and agonizing CD137; and, through various partnerships, is exploring the use of Bicycle® technology to develop therapies for diseases in additional therapeutic areas. Bicycle Therapeutics is headquartered in Cambridge, UK, with many key functions and members of its leadership team located in Lexington, Mass. For more information, visit bicycletherapeutics.com. View source version on businesswire.com: https://www.businesswire.com/news/home/20260420659430/en/ **Investors:** Matthew DeYoung Argot Partners ir@bicycletx.com 212-600-1902 **Media:** Argot Partners media@bicycletx.com Source: Bicycle Therapeutics plc ### Related Stocks - [BCYC.US](https://longbridge.com/en/quote/BCYC.US.md) ## Related News & Research - [09:42 ETNational Kidney Foundation and U.S. Pharmacy Organizations Call for Transition to Race-Agnostic eGFR in Medication Decision-Making](https://longbridge.com/en/news/289065527.md) - [Can Pfizer's dividend survive the patent cliff? This $10.5 billion cancer bet could hold the answer.](https://longbridge.com/en/news/288938490.md) - [Is Adaptive Biotechnologies (ADPT) Turning clonoSEQ’s MRD Momentum Into a Durable Competitive Moat?](https://longbridge.com/en/news/289276171.md) - [Fresenius Medical Care unit Interwell Health posts USD 273 million shared savings in CMS kidney care model](https://longbridge.com/en/news/289323354.md) - [](https://longbridge.com/en/news/288700390.md)